World Congress on Parkinson’s Disease and Related Disorders (IAPRD)
May 2025
Duration of “Good On” time per dose: Immediate-release carbidopa-levodopa vs.
extended-release carbidopa-levodopa (CREXONT® (IPX203))
Duration of “Good On” time per dose: Immediate-release carbidopa-levodopa vs.
extended-release carbidopa-levodopa CREXONT® (IPX203)

Robert A. Hauser, Hubert H. Fernandez, Joohi Jimenez-Shahed, Simon Allard, Ghazal Banisadr, Stanley Fisher, Richard D’Souza

View Poster
The International Parkinson and Movement Disorder Society (MDS)
September 2024
“Good On” Time and Reducing Dyskinesia
Impact of CREXONT® (IPX203) on Parkinson’s patients’ motor states upon awakening: analysis of patient diary data

Stuart H. Isaacson, Hubert H. Fernandez, Camilla Kilbane, Ghazal Banisadr, Arkadiy Pitman, Stanley Fisher, Richard D’Souza

View Poster
August 2023
“Good On” Time and Reducing Dyskinesia
What change to expect in duration of benefit per dose when switching from immediate-release CD-LD to CREXONT® (IPX203)

Robert A. Hauser, Simon Allard, Ghazal Banisadr, Stanley Fisher

View Poster
August 2023
“Good On” Time and Reducing Dyskinesia
How to Dose Extended-Release Carbidopa-Levodopa Capsules CREXONT® (IPX203) in Patients With Parkinson’s Disease: Experience From the Phase 3 Clinical Trial

Robert A. Hauser, Ghazal Banisadr, Stanley Fisher, Hester Visser, Richard D’Souza

View Poster
September 2022
“Good On” Time and Reducing Dyskinesia
Dose Conversion From Immediate-Release Carbidopa-Levodopa to CREXONT® (IPX203) in Parkinson’s Disease Patients With Motor Fluctuations

Robert A. Hauser, Alberto J. Espay, William Ondo, Beth Safirstein, Henry Moore, Rajeev Kumar, Ghazal Banisadr, Stanley Fisher

View Poster
American Academy of Neurology (AAN)
April 2025
Conversion to CREXONT® (IPX203) from IR CD-LD in the RISE-PD phase 3 trial improved aspects of sleep as measured by the Parkinson’s disease sleep scale-2 (PDSS-2)
Conversion to CREXONT® (IPX203) from immediate-release carbidopa-levodopa in the RISE-PD phase 3 trial improved aspects of sleep as measured by the Parkinson’s disease sleep scale-2 (PDSS-2)

William Ondo, Robert A. Hauser, Zachary Grieb, Ghazal Banisadr, Stanley Fisher

View Poster
April 2025
Impact of concomitant therapy with a dopamine agonist on converting patients with Parkinson’s disease from immediate-release carbidopa-levodopa to CREXONT® (IPX203)
Impact of concomitant therapy with a dopamine agonist on converting patients with Parkinson’s disease from immediate-release carbidopa-levodopa to CREXONT® (IPX203)

Rajesh Pahwa, Neepa Patel, Drew Falconer, Simon Allard, Ghazal Banisadr, Stanley Fisher

View Poster
April 2023
“Good On” Time and Reducing Dyskinesia
Integrated safety summary from Phase 3 clinical trials of CREXONT® (IPX203), an extended-release carbidopa-levodopa formulation, in Parkinson’s Disease

Hubert H. Fernandez, Robert A. Hauser, Vanessa K. Hinson, Nirav Pavasia, Eric Molho, Leonid Zeitlin, Hester Visser, Richard D’Souza

View Poster
April 2022
“Good On” Time and Reducing Dyskinesia
Duration of Benefit Per Dose: Post Hoc Analysis of “Good On” Time Per Dose for CREXONT® (IPX203) vs immediate-release carbidopa-levodopa in the RISE-PD Phase 3 Trial

Robert A. Hauser, Hubert H. Fernandez, Kevin Klos, Susan Criswell, Neepa Patel, Ghazal Banisadr, Stanley Fisher

View Poster
Pan American Parkinson’s Disease and Movement Disorders Congress (MDS-PAS)
February 2025
Extended-release carbidopa-levodopa: How is CREXONT® (IPX203) different from IPX066?
Extended-release carbidopa-levodopa: How is CREXONT® (IPX203) different from RYTARY® (IPX066)?

Robert A. Hauser, Aaron Ellenbogen, Ghazal Banisadr, Stanley Fisher, Richard D’Souza

View Poster
May 2022
“Good On” Time and Reducing Dyskinesia
Design of Better Oral Levodopa Delivery: Formulation Strategy of CREXONT® (IPX203), an Investigational Extended-Release Carbidopa-Levodopa

Rohit Dhall, Pinky Agarwal, Camilla Kilbane, Ramon Gil, Aaron Ellenbogen, Ghazal Banisadr, Richard D’Souza, Peter LeWitt

View Poster
Sign Up and Stay Connected
Sign up for the Expert Institute for Parkinson’s Disease newsletter subscription to receive product information, educational tools, resources, and more!
See more